Aytu BioPharma, Inc.
AYTU
Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 yeaā¦ read more
Healthcare
Drug ManufacturersāSpecialty & Generic
17 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.23
Price+3.72%
$0.08
1Y
Price
Market Cap
$23.935m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.+23.7%
EBITDA Margin+14.2%
Net Profit Margin-4.4%
Free Cash Flow Margin+23.7%
EBITDA Margin+14.2%
Net Profit Margin-4.4%
Free Cash Flow MarginRevenue
$56.599m
-4.0%
1y CAGR-13.8%
3y CAGR-7.6%
5y CAGREarnings
-$34.055m
+3.6%
1y CAGR+8.4%
3y CAGR+27.4%
5y CAGREPS
-$4.58
-41.2%
1y CAGR+9.1%
3y CAGR+30.1%
5y CAGRBook Value
$35.143m
$111.689m
Assets$76.546m
Liabilities$22.938m
DebtDebt to Assets
20.5%
-0.3x
Debt to EBITDAFree Cash Flow
$1.644m
+71.8%
1y CAGR-20.8%
3y CAGR+4.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company